Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Avidia
Mountain View, California, United Statesavidia.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Avidia developed a new class of human therapeutic proteins called Avimers™, with its lead candidate being an IL‑6 inhibitor for inflammation and autoimmune diseases. The lead program was in Phase 1 clinical trials at the time of acquisition by Amgen. The Avimer platform allowed engineering modular protein therapeutics targeting multiple disease areas with potential advantages in activity, safety profile, and manufacturing.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Protein therapeutics (Avimer™ proteins)
- Industry
- Biotech
Beyond the preview
Go deeper on Avidia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avidia.